Archives: 2022-04-07

ALY101 molecule holds promise in potential therapies for cancer and rare diseases

Researchers at the University of California, Irvine and the Italian Institute of Technology have developed a new molecule, ALY101, that shows promising anti-cancer activity against a wide range of tumor cell types and in mouse models of a common type of melanoma. The findings, “Structure-based Design of CDC42 Effector Interaction Inhibitors for the Treatment of

Read More


Penn Medicine Study: Pulse Oximeters Did Not Change Outcomes for Patients in COVID-19 Monitoring Program

Already monitored for worsening symptoms via automated text messages, patients with pulse oximeters in the COVID Watch program had similar recovery to those without them. Using a pulse oximeter to measure oxygen levels is no better than just regularly asking patients with COVID-19 if they are short of breath, according to new research at the

Read More


Covid-19 increases the risk of blood clots up to six months after infection

The risk of pulmonary embolism and venous thrombosis is multiplied by a corona infection. According to a new study of all those who tested positive in Sweden, this applies six months after the diagnosis. According to a study, people infected with SARS-CoV-2 have an increased risk of developing severe blood clots for up to six months after infection . According

Read More


A Mount Sinai-led team developed a reproducible and scalable method to advance maturation of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs)

A study reporting this new protocol was published in the April 7 print edition of the journal Cell Stem Cell. A Mount Sinai-led team has developed a reproducible and scalable method to advance maturation of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs)—cells that support heart muscle contraction, generated in the lab from human stem cell lines—which researchers

Read More


Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

BACKGROUND Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5 (AAV5)–based gene-therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-selective promoter. The efficacy and safety of the therapy were previously evaluated in men with severe hemophilia A in a phase 1–2 dose-escalation study. METHODS Was conducted an open-label, single-group, multicenter, phase 3

Read More


CAR T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein (NAP) from Helicobacter pylori to better fight cancer

Immunotherapy is increasingly becoming a successful way to treat cancer. Researchers at Uppsala University have now developed armed CAR-T cells that reinforce the immune defense against cancer and that could increase the possibilities to successfully treat solid tumors. The study has been published in the journal Nature Biomedical Engineering. The use of immunotherapy to treat cancer

Read More


SARS-CoV-2 triggers massive inflammation: result of a study published by Children’s Hospital in Nature

A study led by researchers at Boston Children’s Hospital explains for the first time why COVID-19 causes severe inflammation in some people, leading to acute respiratory distress and multi-organ damage. Surprisingly, the study also finds that antibodies that people develop when they contract COVID-19 can sometimes lead to more inflammation, while antibodies generated by mRNA

Read More


Johns Hopkins-Led Study Finds Convalescent Plasma Can Be Effective Early COVID-19 Therapy

Peer-reviewed publication in New England Journal of Medicine validates findings first announced in December The New England Journal of Medicine (NEJM) today published final results of a nationwide multicenter study led by researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health that show plasma from patients who have recovered from COVID-19 and whose blood contains

Read More


Specialized Liver Blood Vessel Identity Factor Required for Regeneration

Researchers at Weill Cornell Medicine have identified a key protein that induces the program to build specialized liver blood vessels. The discovery could lead to engineered replacement hepatic tissue to treat common liver diseases. There are many types of blood vessels in the human body that are functionally different from each other. In the liver,

Read More


Johns Hopkins-Led Study Finds Convalescent Plasma Can Be Effective Early COVID-19 Therapy

Peer-reviewed publication in New England Journal of Medicine validates findings first announced in December The New England Journal of Medicine (NEJM)  published final results of a nationwide multicenter study led by researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health that show plasma from patients who have recovered from COVID-19 and whose blood

Read More